CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio0.29
Current Ratio2.43
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio-15.87
Forward P/E Ratio-25.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales9.10
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-59.38
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-115.91%
Return on Equity-158.93%
Return on Assets-19.78%
Miscellaneous
Employees179
Outstanding Shares35,280,000
Market Cap$437.16
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $14.05 million during the quarter, compared to analysts' expectations of $13.91 million. CareDx had a negative return on equity of 158.93% and a negative net margin of 115.91%. View CareDx's Earnings History.
What price target have analysts set for CDNA?
4 brokers have issued 1-year price targets for CareDx's stock. Their predictions range from $6.50 to $17.00. On average, they anticipate CareDx's share price to reach $12.1250 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View Analyst Ratings for CareDx.
What is the consensus analysts' recommendation for CareDx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (7/11/2018)
- 2. HC Wainwright analysts commented, "We currently estimate that over 5,700 and 15,000 AlloSure tests could be performed in 2018 and 2019, respectively. Our current estimated enterprise value of the firm is $545M, up from $510M. Excluding $15M debt and assuming 35.5M shares outstanding at the end of 2Q19, this translates to a per share value of approximately $15. Therefore, we have raised our 12-month price target to $15 from $14 per share. Considering CDNA shares are currently trading slightly above $15 a share, we are downgrading our rating to Neutral from Buy." (6/19/2018)
Are investors shorting CareDx?
CareDx saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 3,226,815 shares, an increase of 124.3% from the June 15th total of 1,438,444 shares. Based on an average daily trading volume, of 1,974,197 shares, the days-to-cover ratio is presently 1.6 days. Approximately 13.0% of the shares of the company are sold short. View CareDx's Current Options Chain.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Natera (NTRA), RadNet (RDNT), InVitae (NVTA), Veracyte (VCYT), Enzo Biochem (ENZ), Celcuity (CELC), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and CBA Florida (CBAI).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Dr. Peter Maag, Pres, CEO & Director (Age 51)
- Mr. Michael Bell, Chief Financial Officer (Age 49)
- Dr. James P. Yee, Chief Medical Officer (Age 69)
- Dr. Mitchell J. Nelles, Chief Operating Officer (Age 65)
- Dr. John J. Sninsky Ph.D., Chief Scientific Officer (Age 68)
Has CareDx been receiving favorable news coverage?
Press coverage about CDNA stock has trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a media sentiment score of 0.11 on Accern's scale. They also assigned headlines about the company an impact score of 45.76 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are CareDx's major shareholders?
CareDx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ALGER ASSOCIATES INC (10.49%), MIDROC INVEST AB (4.50%) and Bank of Montreal Can (0.04%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.
Which institutional investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold CareDx company stock in the last year include James P Yee, Mitchell J Nelles and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $12.43.
How big of a company is CareDx?
CareDx has a market capitalization of $437.16 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (NASDAQ CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
